Colorectal Cancer

AbGn-107

Trial

Therapeutics

AbGn-107

Disease Population

The number of new cases of colorectal cancer was 39.4 per 100,000 men and women per year. The number of deaths was 14.5 per 100,000 men and women per year. These rates are age-adjusted and based on 2011-2015 cases and deaths.
Approximately 4.2 percent of men and women will be diagnosed with colorectal cancer at some point during their lifetime, based on 2013-2015 data.
In 2015, there were an estimated 1,332,085 people living with colorectal cancer in the United States[1]. AbGn-107 binds to approximately 15% of colorectal tumors.
Trial Description
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
Trial Center
Phoenix, AZ Mayo Clinic
  • Phoenix, Arizona, United States, 85054
  • Sandra Gawlowski
  • 480-342-6073
  • gawlowski.sandra@mayo.edu
San Francisco, CA University of California
  • San Francisco, California, United States, 94143
  • Hannah McKenna
  • 415-353-8449
  • Hannah.Mckenna@ucsf.edu
Boston, MA Massachusetts General Hospital
  • Boston, Massachusetts, United States, 02114
  • Eamala Sundaram
  • 617-724-2332
  • sundaram.eamala@mgh.harvard.edu
Boston, MA Beth-Israel Deaconess Medical Center
  • Boston, Massachusetts, United States, 02215
  • Justin Sun
  • 617-975-7463
  • jsun7@bidmc.harvard.edu
Boston, MA Dana-Farber Cancer Institute
  • Boston, Massachusetts, United States, 02215
  • Samantha Schuetz
  • 617-632-5575
  • SamanthaR_Schuetz@DFCI.HARVARD.EDU
Seattle, WA University of Washington, Seattle Cancer Care Alliance
  • Seattle, Washington, United States, 98109
  • Camille Biggins
  • 206-606-1646
  • cbiggins@seattlecca.org
Taichung, TW China Medical University Hospital
  • Taichung, Taiwan, 404
  • Yu-Ting Ho
  • 04-22052121 ext 5057
  • blessyou1982@gmail.com
Tainan, TW National Cheng Kung University Hospital
  • Tainan, Taiwan, 48
  • Ray-Fan Su
  • 0910-876172
  • srf106@gmail.com
Taipei, TW National Taiwan University Hospital
  • Taipei, Taiwan, 100
About Colorectal Cancer
Colorectal cancer (CRC) affects the colon and rectum. Globally, CRC is the third most commonly diagnosed cancer in males and the second in females, with 1.65 million new cases and almost 835,000 deaths in 2015 [2]. With current advances in screening techniques and improvements in treatments, the death rate from CRC is declining. Still, it remains the third most common cause of cancer-related death in the world [3].

The CRC cells start in the inner lining of the colon and/or rectum, slowly growing through some or all of its layers. It typically starts as a growth of tissue called a polyp. A particular type of polyp, called an adenoma, can then develop into cancer.
Citations
1. Cancer Stat Facts: Colorectal Cancer. NIH. Available at
2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017; 3:524.
3. World Health Organization. Cancer. WHO. Available at
Details about AbGenomics Clinical Trial can be found atClinicalTrials.gov